KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) EBITDA Margin (2020 - 2023)

Historic EBITDA Margin for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to 516.51%.

  • AbCellera Biologics' EBITDA Margin fell 3746300.0% to 516.51% in Q4 2023 from the same period last year, while for Dec 2023 it was 385.86%, marking a year-over-year decrease of 4181700.0%. This contributed to the annual value of 574.05% for FY2024, which is 1881800.0% down from last year.
  • AbCellera Biologics' EBITDA Margin amounted to 516.51% in Q4 2023, which was down 3746300.0% from 426.9% recorded in Q3 2023.
  • AbCellera Biologics' EBITDA Margin's 5-year high stood at 59.7% during Q2 2020, with a 5-year trough of 516.51% in Q4 2023.
  • For the 4-year period, AbCellera Biologics' EBITDA Margin averaged around 120.79%, with its median value being 22.0% (2022).
  • As far as peak fluctuations go, AbCellera Biologics' EBITDA Margin skyrocketed by 4405300bps in 2022, and later crashed by -4518800bps in 2023.
  • Quarter analysis of 4 years shows AbCellera Biologics' EBITDA Margin stood at 56.28% in 2020, then dropped by -24bps to 42.76% in 2021, then crashed by -432bps to 141.88% in 2022, then tumbled by -264bps to 516.51% in 2023.
  • Its EBITDA Margin was 516.51% in Q4 2023, compared to 426.9% in Q3 2023 and 302.37% in Q2 2023.